Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Apr 15;111(8):4048-54.
doi: 10.1182/blood-2007-09-111708. Epub 2008 Feb 6.

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)

John A Thompson  1 , Richard I Fisher, Michael Leblanc, Stephen J Forman, Oliver W Press, Joseph M Unger, Auayporn P Nademanee, Patrick J Stiff, Stephen H Petersdorf, Alexander Fefer
Affiliations
Clinical Trial

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)

John A Thompson et al. Blood. .

Abstract

To determine the effect of posttransplantation immunotherapy with IL-2 on the progression-free survival (PFS) and overall survival (OS) of patients with non-Hodgkin lymphoma (NHL) after autologous stem-cell transplantation (PBSCT), patients with previously treated NHL were treated with cyclophosphamide, etoposide, total body irradiation (TBI), and PBSCT. Twenty-eight to 80 days after PBSCT, patients were randomized to IL-2 versus observation. Three hundred seventy-six eligible patients were registered (with 4-year PFS of 34% and 4-year OS of 52%), and 194 eligible patients were randomized to continuous infusion intravenous IL-2 (9 million units/m(2)/day for 4 days followed 5 days later by 1.6 million units/m(2)/day for 10 days) versus observation. In randomized patients, there was no significant difference in PFS (hazard ratio of IL-2 to observation = 0.90; P =.56) or in OS (hazard ratio of IL-2 to observation = 0.88; P =.55). There were no deaths related to IL-2 treatment. Grade 4 IL-2-related toxicities (n = 14) were reversible. These results confirm earlier SWOG findings that cyclophosphamide, etoposide, TBI, and PBSCT can be administered to patients with relapsed/refractory NHL with encouraging PFS and OS. Posttransplantation IL-2 given at this dose and schedule of administration had no significant effect on PFS or OS. This study is registered at www.clinicaltrials.gov as NCT00002649.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Disposition of patients.
Figure 2
Figure 2
(A) Progression-free survival from initial registration (all patients). (B) Overall survival from initial registration (all patients).
Figure 3
Figure 3
(A) Progression-free survival from initial registration by chemosensitivity status. (B) Overall survival from initial registration by chemosensitivity status.
Figure 4
Figure 4
(A) Progression-free survival from randomization by treatment arm. (B) Overall survival from randomization by treatment arm.
See this image and copyright information in PMC

References

    1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545. - PubMed
    1. Philip T, Armitage J, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493–1498. - PubMed
    1. Petersen F, Appelbaum F, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol. 1990;8:638–647. - PubMed
    1. Petersen F, Buckner C, Appelbaum F, et al. Etoposide, cyclophosphamide, and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a Phase 1 study. Bone Marrow Transplantation. 1992;10:83–88. - PubMed
    1. Blume K, Forman S. High-dose etoposide (VP-16) containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematological malignancies. Sem Oncol. 1992;19:63–66. - PubMed

Publication types

MeSH terms

Associated data